DxC 500 AU Clinical Chemistry Analyzers: 1. AU w/out ISE, Part No. C63519 2. AU w/ISE, Part No. C63520
원자료는 미국 FDA 발표(영문)입니다. 상품명·사유는 원문 그대로 표기합니다.
Beckman Coulter has identified a software issue affecting DxC 500 AU Clinical Analyzers when testing plasma samples. Following user configuration of a Clinical Chemistry test to use units different from the system default, a subsequent configuration change and activation of the draft configuration in the System Configuration page may cause the analyzer to revert the test units to the system default setting without notifying the user. The system does Pre-Review Reminders Include OII and CDRHRecallGroup@fda.hhs.gov in any discussions on change/elevation of recalls to Class I classification and situations involving additional public communications (FDA and/or firm issued). Post-Review Reminders Final Check: Ensure your documentation accurately reflects the final recommendation prior to signature. Complete CTS: Recall Product tab, Additional Recall Event Info, Regulation, and Act. Upload PDFs of Consult, Review Memo, and Classification Letter for Class I Recall in DocMan. [Click to enter extra reminder]To add reminders, type the reminder in the text field to the left then press the Tab key. Doc ID 03534.05.06 2 of 8 not provide a warning or notification to alert the user that the configured units have reverted to the default units. This issue can result in falsely elevated reported results.
| 제조·판매사 | Beckman Coulter Inc. |
|---|---|
| 리콜 사유 | Beckman Coulter has identified a software issue affecting DxC 500 AU Clinical Analyzers when testing plasma samples. Following user configuration of a Clinical Chemistry test to use units different from the system default, a subsequent configuration change and activation of the draft configuration in the System Configuration page may cause the analyzer to revert the test units to the system default setting without notifying the user. The system does Pre-Review Reminders Include OII and CDRHRecallGroup@fda.hhs.gov in any discussions on change/elevation of recalls to Class I classification and situations involving additional public communications (FDA and/or firm issued). Post-Review Reminders Final Check: Ensure your documentation accurately reflects the final recommendation prior to signature. Complete CTS: Recall Product tab, Additional Recall Event Info, Regulation, and Act. Upload PDFs of Consult, Review Memo, and Classification Letter for Class I Recall in DocMan. [Click to enter extra reminder]To add reminders, type the reminder in the text field to the left then press the Tab key. Doc ID 03534.05.06 2 of 8 not provide a warning or notification to alert the user that the configured units have reverted to the default units. This issue can result in falsely elevated reported results. |
| 위해 등급 | Class II (Class II · 중간) |
| 진행 상태 | Ongoing |
| 보고일 | 2026년 10월 14일 |
| 리콜 개시일 | 2026년 9월 2일 |
| 지역 | CA, United States |
| 유통 범위 | Worldwide - US Nationwide distribution. |
| 수량 | 146 US, 170 OUS |
| 코드/로트 | Software version 1.4.5 or earlier. 1. UDI-DI 14987666545058 2. UDI-DI 14987666545065 |
| 구분 | Voluntary: Firm initiated |
| 리콜 번호 | Z-0084-2027 |
공식 출처
U.S. FDA — Recalls, Market Withdrawals & Safety Alerts fda.gov ↗리콜 번호로 FDA 공식 사이트에서 다시 확인할 수 있습니다. (리콜 번호: Z-0084-2027)
openFDA (U.S. Food & Drug Administration) — food/drug/device enforcement · CC0 1.0 (public domain)
관련 정보 더 찾기
위 링크는 리콜 번호·제품명으로 외부 검색을 여는 것이며, 검색 결과의 내용은 각 매체·사이트의 책임입니다.
이 페이지는 미국 FDA 데이터를 정리한 생활정보이며 의료 조언이 아닙니다. 정확한 내용은 FDA 공식 발표와 제조사 안내로 확인하세요.